idw – Informationsdienst Wissenschaft
Nachrichten, Termine, Experten
Nachrichten, Termine, Experten
Researchers at Helmholtz Munich have secured three prestigious Proof of Concept Grants from the European Research Council (ERC). This funding will enable them to advance innovative projects across diverse areas of biomedical research. With a total of 69 ERC grants to date, Helmholtz Munich continues to establish itself as one of Europe’s leading centers of research excellence.
Here are the winning projects in detail:
FERADICATE: Harnessing Ferroptosis to Combat Aggressive Cancer
The research initiative led by Prof. Marcus Conrad, FERADICATE, is a new approach to treating some of the most aggressive and treatment-resistant cancers. These cancers often carry a poor prognosis and tend to relapse even after targeted therapies. At the heart of FERADICATE is ferroptosis, an iron-dependent form of cell death that cancer cells typically evade. By targeting a key protein known as FSP1, Conrad and his team aim to push cancer cells into this self-destruction process. The team is currently advancing a new class of FSP1 inhibitors, with a focus on improving their selectivity, efficacy, and suitability for oral use. The goal is to offer new hope to patients who currently have limited options. If successful, FERADICATE could pave the way for clinical trials and future partnerships, offering a promising new weapon in the fight against some of the most challenging cancers.
CellCourier: Programmable Drug Delivery
In the CellCourier project, Prof. Fabian Theis and his team are integrating single-cell genomics, advanced computational models, and generative AI to address one of the biggest challenges in drug therapy, namely precise targeting. The aim is to precisely program drug delivery via combinatorial cell targeting and generative design of tailored binding peptides. By leveraging data from the Human Cell Atlas and AI models like Nicheformer and Prophet, the researchers generate “surface codes” – molecular maps that guide these binding peptides. Initially, CellCourier will focus on lung diseases such as COPD, cystic fibrosis, and lung cancer. Alongside technical development, the team is prioritizing intellectual property strategies and exploring commercialization pathways. By enabling more precise delivery, CellCourier has the potential to reduce side effects and improve the safety of mRNA-based and other treatments, contributing to the future of more targeted and effective therapeutics.
SAW2See: Single-Cell Analysis Using Acoustic Waves Traveling on Chip Surfaces
The SAW2See project, led by Prof. André C. Stiel, is rethinking single-cell diagnostics by moving away from bulky, costly optical systems. Instead, in collaboration with the Leibniz Institute for Solid State and Material Research, SAW2See uses point source optimized interdigital transducers (IDTs) directly integrated in microfluidic chips. These transducers detect optical absorption signatures via the photoacoustic effect. Such absorbance signatures can be valuable indicators for conditions such as red blood cell disorders or melanoma when using visible light, and potentially for detailed chemical fingerprinting in the infrared range. By combining mass-producible chips with compact laser diodes, the technology aims to enable high-throughput, cell-level analysis in a more affordable and scalable format. Next steps include technical refinement, benchmarking for diagnostic applications, and expanding into mid-infrared analysis. If successful, SAW2See could advance early and accessible diagnostics, particularly for point-of-care and decentralized healthcare settings.
About Helmholtz Munich
Helmholtz Munich is a leading biomedical research center. Its mission is to develop breakthrough solutions for better health in a rapidly changing world. Interdisciplinary research teams focus on environmentally triggered diseases, especially the therapy and prevention of diabetes, obesity, allergies, and chronic lung diseases. With the power of artificial intelligence and bioengineering, researchers accelerate the translation to patients. Helmholtz Munich has around 2,500 employees and is headquartered in Munich/Neuherberg. It is a member of the Helmholtz Association, with more than 43,000 employees and 18 research centers the largest scientific organization in Germany. More about Helmholtz Munich (Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH): www.helmholtz-munich.de/en
https://erc.europa.eu/apply-grant/proof-concept
Criteria of this press release:
Journalists, Scientists and scholars
Biology, Medicine
transregional, national
Contests / awards
English
You can combine search terms with and, or and/or not, e.g. Philo not logy.
You can use brackets to separate combinations from each other, e.g. (Philo not logy) or (Psycho and logy).
Coherent groups of words will be located as complete phrases if you put them into quotation marks, e.g. “Federal Republic of Germany”.
You can also use the advanced search without entering search terms. It will then follow the criteria you have selected (e.g. country or subject area).
If you have not selected any criteria in a given category, the entire category will be searched (e.g. all subject areas or all countries).
